SynAct Pharma AB (SE:SYNACT)
:SYNACT
Want to see SE:SYNACT full AI Analyst Report?
SYNACT Stock Chart & Stats
kr23.80
-kr0.24(-1.33%)
At close: 4:00 PM EST
kr23.80
-kr0.24(-1.33%)
Day’s Range― - ―
52-Week Rangekr13.40 - kr25.30
Previous CloseN/A
Volume43.49K
Average Volume (3M)214.83K
Market Cap
kr765.82M
Enterprise Valuekr695.02M
Total Cash (Recent Filing)kr68.89M
Total Debt (Recent Filing)kr1.54M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding53,330,242
10 Day Avg. Volume154,831
30 Day Avg. Volume214,829
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance-sheet FlexibilityVery low debt reduces refinancing and interest-rate risks, preserving optionality for a clinical-stage biotech. This balance-sheet flexibility supports continued R&D spending or strategic partnering without immediate debt pressure, a durable advantage for multi-stage development.
Focused Pipeline And MechanismA clearly defined lead program with a specific mechanism (melanocortin receptor agonist) focuses resources and de-risks discovery-stage exposure. A targeted, potentially differentiated oral candidate enhances appeal to partners and creates a durable strategic narrative for execution and licencing.
Partnership / Out-licensing Monetization ModelA business model centered on partnerships and licensing fits a clinical-stage biotech: it avoids building costly commercial infrastructure and allows value capture via milestone and royalty streams. Structurally, this model scales upside while keeping fixed costs lower long term.
Bears Say
Persistent Negative Cash Flow / Heavy BurnSustained negative operating and free cash flow indicates ongoing funding needs and erodes runway. Over months this forces repeat financing or dilutive deals, constraining strategic choices and increasing execution risk for advancing clinical programs to value-inflection points.
Pre-revenue With Widening Net LossesAbsence of recurring revenue and growing annual losses heighten dependence on external capital and milestone outcomes. Without commercialization or sustained partnering receipts, profitability remains unattainable in the near term, increasing downside if trials delay or fail.
Declining Equity / Funding PressureA meaningful drop in equity signals funding consumption and potential dilution or valuation effects. This persistent draw on shareholders' capital pressures future financing terms and could weaken negotiating leverage for partnerships or licensing, affecting long-term program financing.
SynAct Pharma AB News
SYNACT FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was kr13.40 and its highest was kr25.30 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is kr765.82M.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is May 27, 2026 which is in 4 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on Feb 18, 2026. The company reported -kr0.43 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.43.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 53,330,242 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -kr0.43 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.407%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in SE:SYNACT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.
Technical Analysis
Oncopeptides AB
―
Saniona AB
―
Ascelia Pharma AB
―
Guard Therapeutics International AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---